Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

HemaSphere·2025
Same author

Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single-cell RNA sequencing.

Molecular oncology·2024
Same author

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.

Leukemia·2024
Same author

Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.

British journal of haematology·2023
Same author

Editorial: Biology and treatment of high-risk CLL.

Frontiers in oncology·2023
Same author

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Frontiers in oncology·2023

Related Experiment Video

Updated: May 8, 2026

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

TP53 aberrations in chronic lymphocytic leukemia.

Martin Trbusek1, Jitka Malcikova

  • 1Department of Molecular Medicine, Central European Institute of Technology, Masaryk University (CEITEC MU), Kamenice 5, 62500, Brno, Czech Republic, mtrbusek@fnbrno.cz.

Advances in Experimental Medicine and Biology
|September 10, 2013
PubMed
Summary
This summary is machine-generated.

Chronic lymphocytic leukemia (CLL) patients with TP53 defects face poor prognoses and limited treatment options. Current therapies are often ineffective, leading to aggressive relapse and short survival, highlighting the need for novel therapeutic strategies.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • TP53 defects present a significant therapeutic challenge in Chronic Lymphocytic Leukemia (CLL), associated with poor response to standard treatments and dismal survival rates.
  • The prevalence of TP53 defects increases with disease progression and in Richter transformation, complicating treatment strategies.
  • Current diagnostic methods primarily focus on 17p deletion, potentially underestimating the true incidence of TP53 abnormalities which also include mutations.

Purpose of the Study:

  • To highlight the clinical challenges posed by TP53 defects in CLL patients.
  • To review the current treatment landscape and its limitations for this patient subgroup.
  • To emphasize the need for developing novel therapeutic approaches for TP53-altered CLL.

Main Methods:

  • Review of existing literature on TP53 defects in CLL.
  • Analysis of patient data regarding treatment response and survival outcomes.
  • Comparison of diagnostic methods for TP53 alterations.

Main Results:

  • TP53-defective CLL patients exhibit median survival of 3-4 years, regardless of treatment modality.
  • These patients respond poorly to DNA-damaging agents and are prone to aggressive relapse.
  • ATM gene mutations, while affecting the p53 pathway, confer a better prognosis than TP53 abnormalities.

Conclusions:

  • TP53 defects represent a critical negative prognostic factor in CLL, necessitating specialized therapeutic strategies.
  • Alemtuzumab and allogeneic stem cell transplantation are current mainstays for TP53-altered CLL, despite ongoing research into novel agents.
  • Accurate detection of both TP53 deletions and mutations is crucial for effective patient management and therapeutic decision-making.